The global epidemic of infection by HIV has created an urgent need for new classes of
antiretroviral agents. The potent ability of small interfering (si) RNAs to inhibit the expression
of complementary RNA transcripts is being exploited as a new class of therapeutics for a
variety of diseases including HIV. Many previous reports have shown that novel RNAi-based
anti-HIV/AIDS therapeutic strategies have considerable promise; however, a key obstacle to
the successful therapeutic application and clinical translation of siRNAs is efficient delivery …